The financial quarter was essentially in line with expectations. Reported EPS was -$0.84, matching the published consensus of roughly -$0.84; revenue was zero, also expected for a pre-commercial biotech.
| Metric | Q2 2026 | Q2 2025 | Filing comparison |
|---|---|---|---|
| Revenue | $0 | $0 | No change (Financial Highlights) |
| Net loss | $109.9 million | $110.0 million | Essentially flat (Financial Highlights) |
| Net loss per share | $0.84 | $0.98 | Improved, helped partly by a larger share base (Financial Highlights) |
| R&D expense | $58.2 million | $62.4 million | Down 7% (Financial Highlights) |
| G&A expense | $50.7 million | $49.7 million | Up 2% (Financial Highlights) |
| Cash, equivalents and marketable securities | $492.1 million | $295 million | Versus June 30, 2025; includes $62.8 million of ATM proceeds (Balance Sheets; Financial Highlights) |
The key value driver remains the September 30, 2026 FDA decision window, not the income statement. The BLA review is still described as on track, and the second fill-finish facility's data package has been submitted with review progressing; that creates a backup manufacturing route if the Catalent Indiana site remains unresolved (SMA Program). However, the second-facility strategy was already part of the prior quarter's setup, so this filing mostly confirms execution rather than creating a fresh regulatory upside surprise.
Manufacturing risk is reduced but not eliminated. The company says ample commercial supply is available from the second facility, but FDA inspection classification for Catalent Indiana remains pending, and European timing is still dependent on regulatory alignment (SMA Program). That leaves the U.S. PDUFA date intact while preserving a material operational uncertainty around the original facility and the European filing.
The balance sheet is stronger, though partly funded by dilution. Cash rose to $492.1 million from $367.6 million at December 31, 2025, but the quarter included $62.8 million of net ATM proceeds, meaning the improved runway came with additional equity issuance (Balance Sheets; Financial Highlights). Operating expenses remain substantial at roughly $109 million for the quarter, so the cash position primarily supports the launch and regulatory bridge rather than signaling an inflection in operating performance.
The net read is mildly mixed: regulatory preparation is solid, but nothing materially exceeded the standing setup. Initiating the Phase 2 FORGE study adds longer-term pipeline optionality, while OPAL, the subcutaneous formulation, and SRK-439 continue without a decisive new data catalyst (FSHD Program; SMA Program; SRK-439 Program). Against a market already expecting a September FDA decision and a second manufacturing path, the filing is reassuring execution—not a clear beat.
Read the original 8-K on SEC EDGAR ↗